Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology

  • STATUS
    Recruiting
  • End date
    Sep 30, 2022
  • participants needed
    400
  • sponsor
    Nantes University Hospital
Updated on 5 March 2021
Investigator
YANN PEREON, MD-PHD
Primary Contact
Chru Brest (0.4 mi away) Contact
+14 other location
fasting
autosomal dominant
amyloidosis
diflunisal
amyloid protein
pes cavus

Summary

Familial amyloid neuropathy due to transthyretin gene mutations (TTR-FAP) is a rare autosomal dominant inherited disease resulting in the abnormal multi-system deposition of amyloid proteins. These deposits produce a multi-organ disease. AP is usually fatal 10 to 15 years after onset of symptoms if untreated. The prevalence of the disease remains still poorly understood and usually the search for this pathology is done in a third line of investigation. So the average time to diagnosis is extremely long, from 12 to 24 month. Now that the investigators have etiological treatment ( famidis (Vyndaqel) and Diflunisal (Dolobid)) of this disease, it is essential to be able to detect FAP patients as early as possible. With this study, investigator decided to test for TTR mutation all patients presented with neuropathy of unknown etiology at the first line of investigation. The goal of this study is to evaluate the prevalence of FAP-TTR among neuropathy and defined the best strategy to test this population for TTR mutations.

Details
Condition Lattice corneal dystrophy, Cardiac Amyloidosis, Transthyretin Amyloidosis, Hereditary Transthyretin Amyloidosis
Treatment Blood sample
Clinical Study IdentifierNCT03190577
SponsorNantes University Hospital
Last Modified on5 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Adult patient (male and female) aged not more than 90 years old
Patients with neuropathy identified by EDX exam or small fibre neuropathy identified from a skin biopsy
Patients who have undergone the minimal assessment for neuropathy as defined by the HAS (French National Health Authority): biological analysis (fasting glucose, CBC, liver and renal functions, CRP, pituitary TSH)
Patients belonging to the social security system
Patient who gave written informed consent
NON-INCLUSION CRITERIA Patients under legal supervision or guardianship
Patients with a confirmed documented diagnosis of the cause of neuropathy
Patients with evidence of Charcot Marie Tooth neuropathy: very slowly
progressive course, pes cavus
Patients who have already been investigated for a TTR mutation Pregnant women
Minors
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note